Arcus says Gilead-partnered cancer therapy cut death risk by 36%

wildpixel/iStock via Getty Images Arcus Biosciences ( NYSE: RCUS ) announced Tuesday that its anti-PD-1 antibody therapy zimberelimab, developed with Gilead ( NASDAQ: GILD ), caused a 36% reduction in mortality risk as part of a combination regimen in certain patients with lung cancer. Citing data from Part 1 of.